Propanc Biopharma (PPCB) News Today $6.10 0.00 (0.00%) As of 08/7/2025 Add Compare Share Share Headlines Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock PPCB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Propanc Biopharma Issues Promissory Note for CapitalJune 2, 2025 | tipranks.comPropanc Biopharma (OTCMKTS:PPCB) Stock Price Down 53.7% - Should You Sell?February 26, 2025 | marketbeat.comPropanc Biopharma (OTCMKTS:PPCB) Trading Up 108.3% - Still a Buy?January 30, 2025 | marketbeat.comPropanc Biopharma Inc (PPCB)August 21, 2024 | investing.comPropanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North AmericaAugust 14, 2024 | finance.yahoo.comVTXB Vortex Brands Co.May 29, 2024 | seekingalpha.comPropanc Biopharma, Inc. (PPCB)May 29, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent OfficeApril 16, 2024 | finance.yahoo.comPropanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 10, 2024 | stockhouse.comPropanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 8, 2024 | finance.yahoo.comPropanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use StudyFebruary 22, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property OfficeJanuary 16, 2024 | finance.yahoo.comPropanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment OpportunitiesDecember 18, 2023 | finance.yahoo.comPropanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRPDecember 13, 2023 | finance.yahoo.comJames Nathanielsz, CEO of Propanc Biopharma, Inc., is Featured in an Interview With SmallCapsDailyDecember 12, 2023 | finance.yahoo.comPropanc Biopharma, Inc.: Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor CellsNovember 7, 2023 | finanznachrichten.dePropanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor CellsNovember 7, 2023 | finance.yahoo.comPropanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, AustraliaAugust 15, 2023 | finance.yahoo.comPropanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030July 26, 2023 | finance.yahoo.comPropanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 ReadsJuly 13, 2023 | finance.yahoo.comPropanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid TumorsJuly 5, 2023 | finance.yahoo.comPPCB - Propanc Biopharma, Inc.June 30, 2023 | sg.finance.yahoo.comPROPANC BIOPHARMA INC (PPCB) stock forecast and price targetJune 28, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in EuropeMay 25, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North AmericaMay 23, 2023 | finance.yahoo.comPropanc Biopharma Announces Reverse Stock SplitMay 23, 2023 | finance.yahoo.comPropanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic CancerMarch 28, 2023 | finance.yahoo.comPropanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor CellsMarch 16, 2023 | finance.yahoo.comXeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, PredictionsMarch 14, 2023 | benzinga.comPPCB Propanc Biopharma, Inc.February 23, 2023 | seekingalpha.comPropanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)January 11, 2023 | finance.yahoo.comPropanc Biopharma, Inc.: Propanc Biopharma's Joint Researcher Receives Award at Doctoral Conference at the University of JaénDecember 17, 2022 | finanznachrichten.dePropanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of JaénDecember 15, 2022 | finance.yahoo.comPropanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic CancerNovember 30, 2022 | finance.yahoo.comPropanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic CancerNovember 15, 2022 | finance.yahoo.comPropanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor ConferenceOctober 26, 2022 | finance.yahoo.comPropanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17October 12, 2022 | finance.yahoo.comPropanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027September 29, 2022 | finance.yahoo.comPropanc Biopharma Reports Significant Effects of PRP Against the Tumor MicroenvironmentSeptember 8, 2022 | finance.yahoo.comPropanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery ProgramAugust 23, 2022 | finance.yahoo.comPropanc Biopharma, Inc.: Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent OfficeAugust 17, 2022 | finanznachrichten.dePropanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent OfficeAugust 16, 2022 | finance.yahoo.comPropanc Biopharma, Inc.: Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and GranadaAugust 3, 2022 | finanznachrichten.dePropanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and GranadaAugust 3, 2022 | finance.yahoo.comPropanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past DecadeJuly 28, 2022 | finance.yahoo.comPropanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery ProgramJuly 19, 2022 | finance.yahoo.comPropanc Biopharma's CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer PatientsJuly 13, 2022 | stockhouse.comPropanc Biopharma Inc NewsJuly 13, 2022 | thestreet.comPropanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions | MorningstarJuly 6, 2022 | morningstar.comMPropanc Biopharma's CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global JurisdictionsJuly 6, 2022 | stockhouse.com Get Propanc Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for PPCB and its competitors with MarketBeat's FREE daily newsletter. Email Address PPCB Media Mentions By Week PPCB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PPCB News Sentiment▼0.000.38▲Average Medical News Sentiment PPCB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PPCB Articles This Week▼00▲PPCB Articles Average Week Get Propanc Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for PPCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BriaCell Therapeutics News Hepion Pharmaceuticals News Kaya News Viracta Therapeutics News Capstone Therapeutics News NuCana News Vincerx Pharma News Universe Pharmaceuticals News Hero Technologies News Syros Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:PPCB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PPCB Stock Alerts